Literature DB >> 27392514

History of Orphan Drug Regulation-United States and Beyond.

M E Haffner1.   

Abstract

The US Orphan Drug Act, passed in 1982, was the first orphan drug legislation in the world. It is a law based on economic incentives making it financially possible for pharmaceutical firms to develop products for small patient populations. Since passage, many additional countries have developed orphan drug programs and many pharmaceutical firms have developed around the orphan program. Today, more than 500 drugs for rare diseases have been developed in the United States.
© 2016 American Society for Clinical Pharmacology and Therapeutics.

Entities:  

Mesh:

Year:  2016        PMID: 27392514     DOI: 10.1002/cpt.426

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

Review 1.  Emptying the stores: lysosomal diseases and therapeutic strategies.

Authors:  Frances M Platt
Journal:  Nat Rev Drug Discov       Date:  2017-11-17       Impact factor: 84.694

2.  Mining the transcriptome for rare disease therapies: a comparison of the efficiencies of two data mining approaches and a targeted cell-based drug screen.

Authors:  A J Mears; S C Schock; J Hadwen; S Putos; D Dyment; K M Boycott; Alex MacKenzie
Journal:  NPJ Genom Med       Date:  2017-04-24       Impact factor: 8.617

3.  The work, goals, challenges, achievements, and recommendations of orphan medicinal product organizations in India: an interview-based study.

Authors:  Mohua Chakraborty Choudhury; Gayatri Saberwal
Journal:  Orphanet J Rare Dis       Date:  2019-11-04       Impact factor: 4.123

4.  Precision Medicines' Impact on Orphan Drug Designation.

Authors:  Christine M Mueller; Gayatri R Rao; Katherine I Miller Needleman
Journal:  Clin Transl Sci       Date:  2019-07-26       Impact factor: 4.689

5.  Capture and passive predation in times of COVID-19 pandemic.

Authors:  Samira Guennif
Journal:  Public Choice       Date:  2022-10-08
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.